CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, including for patients with biochemical recurrence after local therapy, and apply this information in the discussion of nonresearch treatment options.
  • Review available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and recognize how these approaches are being integrated into clinical management algorithms.
  • Understand how age, comorbidities, prior therapeutic exposure and other clinical and biological factors affect the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC).
  • Assess the available research supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and identify appropriate candidates for available agents and regimens.
  • Appreciate Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with approved therapies for prostate cancer.
  • Recall the design of ongoing clinical trials evaluating other novel therapies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/ProstateCancer/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component. To receive credit, the participant should review the NCPD information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/Prostate/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONS2025/Prostate/Video.
  
  Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/Prostate/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONS2025/Prostate.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rahul Aggarwal, MD
  Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
  Director, Genitourinary Medical Oncology
  University of California, San Francisco
  Department of Medicine
  Division of Hematology/Oncology
  Associate Director for Clinical Research
  UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Advisory Committees: Novartis; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, FibroGen Inc, Flare Therapeutics, Johnson & Johnson Pharmaceuticals, Merck, ORIC Pharmaceuticals, Pfizer Inc, Xencor; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Merck; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium.
  
  Monica Averia, MSN, AOCNP, NP-C
  Oncology Nurse Practitioner
  Clinical Instructor of Medicine
  USC Norris Cancer Center
  Los Angeles, California
  
  No relevant conflicts of interest to disclose.
  
  Kathleen D Burns, RN, MSN, AGACNP-BC, OCN
  Genitourinary Medical Oncology
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Advisory Committees: Eisai Inc, Janssen Biotech Inc, Sumitomo Dainippon Pharma Oncology Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Pfizer Inc, Sumitomo Dainippon Pharma Oncology Inc.
  
  William K Oh, MD
  Director of Precision Medicine
  Yale Cancer Center
  Professor of Medicine, Division of Medical Oncology
  Yale School of Medicine
  Medical Director, Service Line
  Smilow Cancer Hospital at Greenwich Hospital
  New Haven, Connecticut
  
  Advisory Committees: Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Nature's Toolbox Inc, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Stock Options — Private Companies: Nature’s Toolbox Inc; Stock Options/Stock —Public Companies: GeneDx.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Novartis.
  
  Release date: May 2025
  Expiration date: May 2026
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.